Z 160

Drug Profile

Z 160

Alternative Names: MK-6721; NMED-160; Z160

Latest Information Update: 15 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Neuromed Pharmaceuticals
  • Developer Neuromed Pharmaceuticals; Zalicus
  • Class Analgesics; Small molecules
  • Mechanism of Action N type calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Postherpetic neuralgia
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Neuropathic pain; Pain; Postherpetic neuralgia; Stroke

Most Recent Events

  • 11 Nov 2013 Discontinued - Phase-I for Pain in Canada (PO)
  • 11 Nov 2013 Discontinued - Phase-II for Neuropathic pain in USA (PO)
  • 11 Nov 2013 Discontinued - Phase-II for Postherpetic neuralgia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top